Your Personal Pollen Forecast Kenvue’s Hyperlocal Allergy Impact System

Kenvue Brands LLC – the consumer health company behind brands including Zyrtec – has filed a patent for a system that creates a personalised allergy impact profile for individuals, using local environmental data to predict how a specific person will be affected by allergens in their immediate area and recommend appropriate treatment.

The Problem

Allergic rhinitis – commonly known as hay fever – affects a substantial proportion of the global population, causing symptoms including sneezing, nasal congestion, itchy eyes and disrupted sleep. The severity of symptoms varies enormously between individuals and between days, driven by a complex interaction between a person’s specific allergen sensitivities, the actual concentrations of those allergens in their immediate environment, and factors including humidity, temperature and air quality.

Generic allergy forecasts – such as regional pollen count reports – provide some guidance but are of limited practical use for individuals, because they reflect broad area averages rather than the conditions at a specific location, and they treat all sufferers as having the same sensitivity profile. A person who is highly sensitive to grass pollen but not to tree pollen will experience very different symptom severity on a high grass pollen day compared to a high tree pollen day, even if the overall pollen count reported for their region is the same. Similarly, the pollen count in an inner-city apartment with windows closed will differ significantly from that in a suburban garden at the same time.

For allergy sufferers trying to manage their condition – deciding when to take medication, whether to exercise outdoors, whether to open windows – the information available from generic forecasts is simply not precise enough to be genuinely useful. There is a clear opportunity for a more personalised, location-specific approach that accounts for individual sensitivity profiles and hyperlocal environmental conditions.

What This Invention Does

Kenvue’s invention creates an allergy impact profile for a specific individual by combining two inputs: the person’s known allergen sensitivities and the actual environmental conditions at their precise location. The system predicts the impact that local environmental conditions will have on that individual’s allergy symptoms, and recommends treatment in response to the predicted impact.

The system and method are designed to operate in a personalised and hyperlocal manner – hence the title. “Personalised” means the allergy impact assessment is specific to the individual’s unique sensitivity profile, not a generic population average. “Hyperlocal” means the environmental data is sourced for the specific location of the individual, not a broad regional average. By combining both dimensions, the system can deliver predictions and recommendations that are genuinely meaningful for the specific person in the specific place at the specific time.

In practice, this type of system would likely draw on environmental monitoring data including local pollen counts, air quality indices, temperature and humidity, and combine them with the individual’s recorded sensitivity data to generate a predicted symptom impact score. Treatment recommendations would then follow from the predicted impact – suggesting when to pre-treat prophylactically, when symptoms are likely to be manageable without medication, and which specific allergens to be most concerned about on a given day.

Key Features

Individual allergy impact profile. The system creates and maintains a personalised allergy impact profile for each user, reflecting their specific allergen sensitivities rather than applying generic population-level predictions.

Hyperlocal environmental data. Environmental conditions are assessed at the specific location of the individual, capturing the actual allergen exposure relevant to that person rather than relying on broad regional averages.

Predictive symptom impact assessment. The system predicts how identified environmental conditions will affect the individual’s allergy symptoms, providing forward-looking information that enables proactive management.

Treatment recommendation engine. Based on the predicted allergy impact, the system recommends appropriate treatment – whether pre-medication, avoidance behaviour, or monitoring – tailored to the individual’s predicted symptom burden.

Digital health platform architecture. The invention falls within the G16H (health informatics) classification, reflecting its implementation as a digital health system that processes health data to generate personalised clinical recommendations.

Who Is Behind It?

Kenvue Brands LLC is the consumer health business spun out of Johnson and Johnson in 2023, whose portfolio includes well-known over-the-counter health brands. Among these is Zyrtec (cetirizine), one of the world’s most widely used antihistamine brands. The large and multi-disciplinary inventor team – Russel Walters, Thomas Shyr, Matthew Machado, Russell Gould, Grant Hou, Jessica Lienert, Jennifer Callaghan and Christina Lee – reflects the blend of data science, clinical expertise and consumer health knowledge needed to develop a personalised health technology of this kind. The application is filed through Spruson and Ferguson and is a divisional of an earlier filing (AU 2020356525), tracing back to a US provisional application from September 2019.

Why It Matters

Allergic disease is extremely common and significantly undermanaged. Many sufferers either over-medicate (taking antihistamines on days when their symptoms would be mild) or under-medicate (being caught unprepared on high-symptom days because they did not anticipate the impact of local conditions). Better prediction and personalisation has the potential to meaningfully improve both quality of life for sufferers and the appropriate use of allergy medications.

For Kenvue, a technology that can improve the management of allergic conditions has obvious commercial relevance to its antihistamine brands – consumers who understand exactly when they need their medication, and trust that understanding because it is personalised and location-specific, are likely to be more engaged and consistent users. More broadly, the invention represents a significant trend in consumer health: the use of digital tools and personalised data to move from reactive symptom treatment to proactive, prediction-driven health management. As climate change drives longer and more intense pollen seasons in many parts of the world, tools that help individuals manage the growing burden of allergic disease will only become more important.

---

AU 2026201596 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.